CHA Biotech sees big future in CDMO market
![Matica Biotechnology and German bio company Sartorius collaborate to develop real-time process analysis technology and an automation system. [CHA BIOTECH]](https://koreajoongangdaily.joins.com/data/photo/2022/12/20/feb508a1-879a-4e85-b51b-8fa7df4662ac.jpg)
Matica Biotechnology and German bio company Sartorius collaborate to develop real-time process analysis technology and an automation system. [CHA BIOTECH]
As global pharmaceutical and bio groups increase the outsourcing of production in the contract development and manufacturing organization (CDMO) market, CHA Biotech is focusing on innovation in the cell and gene treatment manufacturing sector.
CHA Biotech has conducted extensive research and development into both the knowledge and manufacturing technology required for a range of cell and gene therapies, including stem cells and immunocyte.
Since 2016, CHA Biotech has focused on the U.S. to develop new growth engines and, in 2019, it established its Matica Biotechnology facility in Texas as part of its entry into the cell and gene therapy CDMO market.
Matica Biotechnology, a subsidiary of CHA Biotech, completed construction of the CDMO facility in May this year. The CDMO facility for cell and gene therapy is outfitted to cGMP (current good manufacturing practice) standards recognized by the U.S. Food and Drug Administration.
Companies in the cell gene therapy CDMO market need to be able to provide a customized service following the requests of customer because development and manufacturing working processes are not standardized across the industry. The CDMO facility at Matica Biotechnology uses up-to-date technology in order to respond flexibly to customer requests.
Matica Biotechnology expects revenue to jump from 2023.
“The cell and gene therapy CDMO market is going to grow more than 20 percent annually and will be worth 25 trillion won in 2030” said Matica Biotechnology CEO Song Youn-jung in a statement. “We will get 1 trillion won in yearly sales in 2030 and will make it into the top five gene therapy CDMO companies in the world.”
Matica Biotechnology will also produce viral vectors, which are core materials used for the development of cell and gene therapies, and will cover cell and gene therapy development and production services.
Matica Biotechnology plans to build manufacturing facilities reflecting the requests of client companies and trends in the cell and gene therapy market. Holding company CHA Biotech also plans to expand in the global CDMO market, and is concentrating on investing in Matica Biotechnology facilities.
Besides the CDMO facility completed in May this year, the company has also secured an additional 6,600-square-meter plot for CDMO facility expansion in the future in order to produce medication at the commercialization stage.
Matica Biotechnology has shortened the schedule for the development and production of medication in partnership with Sartorius, a German bio company, and is developing real-time process analysis technology and automation systems in order to ensure uniform product quality.
The company is also working on plasmid DNA and protein research in partnership with Texas A&M University.
The technology that Matica Biotechnology established will be used in the Cell Gene Biobank facility under construction in Pangyo, Gyeonggi.
CHA Biotech plans to stand out in the CDMO market in Europe and Asia by bringing more than 20 years of knowledge and experience to the Cell Gene Biobank facility and combining it with the advanced CDMO technical skills of Matica Biotechnology.
Cell Gene Biobank will be a 10-story building with four basement floors, with a contract and development manufacturing organization (CDMO) facility for cell and gene therapy and a storage facility for stem cells. It will simultaneously take charge of global production of CGT, mRNA, viral vector and plasmid DNA treatments.
BY PARK YE-EUN [park.yeeun@joongang.co.kr]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)